Randomized, Double-Blind Parallel-Group, Phase 3 Multicenter Study to Evaluate the Efficacy of Zelpultide Alfa in Preventing Bronchopulmonary Dysplasia (BPD) in High-Risk Preterm Neonates Compared to Standard of Care (SOC)
Latest Information Update: 15 Apr 2025
At a glance
- Drugs Zelpultide alfa (Primary)
- Indications Bronchopulmonary dysplasia
- Focus Registrational; Therapeutic Use
- Acronyms Zela
- Sponsors Airway Therapeutics
Most Recent Events
- 10 Apr 2025 Status changed from recruiting to active, no longer recruiting.
- 01 Apr 2025 New source identified and integrated (ClinicalTrials.gov NCT06897839)
- 27 Mar 2025 Status changed from planning to recruiting.